


TRI REAGENT® Solutions for TOTAL RNA ISOLATION

- total RNA with unparalleled yield and quality.
- costs less than \$1 per sample (100 mg tissue or 10⁷ cells).

TRI REAGENT® for cells and tissues

TRI REAGENT® BD for whole blood and plasma

TRI REAGENT® LS for liquid samples



The classic single-step method has been significantly improved to provide higher yields, a shorter protocol, and higher quality RNA from difficult sources! In addition, TRI Reagent has made it possible to isolate simultaneously RNA, DNA and proteins.

(Anal. Biochem. 225:163. 1995. Biotechniques. 19:942. 1995.)

Isolated RNA is ready for Northern blotting, RT-PCR, and other applications.

MRC

MOLECULAR RESEARCH CENTER, INC.
5645 Montgomery Rd.

Cincinnati, OH 45212

Phone: 513-841-0900, 888-841-0900
Fax: 513-841-0080

E-mail:info@mrgene.com
Visit our website at:
<http://www.mrgene.com>

- Australia: 800 - 631-093 • India: 11-642-5156
- Switzerland: 41-420-9636 • Italy: 2-26-40274
- Hong Kong: 275-77569 • Austria: 1-292-3527
- Korea: 2-294-6411 • Japan: 3-5632-9605
- France: 3-88-180727 • Israel: 9-947-2563
- Taiwan: 2-752-3350 • Canada: 905-828-2455
- Malaysia: 3-777-2611 • Turkey: 1-212-247-9296
- Germany: 6227-51308, 6172-22073
- Poland: 22-635-2455 • Spain: 1-535-3960

Circle No. 63 on Reader Service Card

LETTERS TO THE EDITOR

IL-16 anti-HIV-1 therapy

To the editor — In the June issue of *Nature Medicine*, Zhou *et al.* raise the exciting possibility that stem cells from HIV-1 infected persons might be engineered to constitutively produce IL-16, creating an infectable population of CD4+ cells that would not support virus replication. The mechanism they hypothesize for their findings, suppression of mRNA expression, is similar to one previously described² where we demonstrated that rIL-16 repressed HIV-1 promoter activity up to 98% in a CD4-dependent fashion. Repression required sequences contained within the core enhancer but was not due to loss of a transcriptional activator protein. Rather, IL-16 appeared to induce a transcriptional repressor. Nanomolar concentrations of rIL-16, similar to the extracellular levels present in the experiments by Zhou *et al.*, repressed HIV-1 LTR-directed expression by 90%.

Zhou *et al.* also found that virus entry is unaffected by IL-16, and that constitutive expression of the C-terminal 130 amino acids of IL-16 is sufficient to completely suppress virus replication. This is important because CD4+ T cells constitutively express IL-16 mRNA³ and proIL-16 and release bioactive IL-16 upon activation (manuscript submitted). Since HIV-1 infects recently activated T cells, it appears that the production of IL-16 by these cells is insufficient to repress virus replication. This lack of effect may be because pretreatment with IL-16 is required to induce transcriptional repression². The problems of delivery of IL-16 *in vivo* may be overcome by the engineered constitutive expression of IL-16 by CD4+ cells.

A few words of caution are appropriate, however. IL-16 has profound effects on CD4+ bone marrow precursors which might alter T or B cell maturation (pers. comm., Paul Szabo, Cornell Medical Center) and it is a potent proinflammatory cytokine with pleiotropic effects on T cell activation. Unregulated, constitutive secretion of IL-16 by bone marrow precursors might have adverse effects. However, there may be therapeutic potential for exogenous IL-16 administration, when dose could be controlled or discontinued.

Independent of its role in repressing HIV-1 replication, IL-16 may be effective in the




Fig. 1 Synergistic effect of IL-16 and IL-2 on CD4+ T cell proliferation. Human peripheral blood mononuclear cells (PBMC) obtained from an HIV-1-infected individual were cultured either as untreated or in the presence of IL-16 (10-10 M) or IL-2 (10 U/ml), or a combination of the two cytokines. The appropriate cultures received IL-16 once a week and/or IL-2 twice a week for up to 6 weeks. The number of CD4+ T cells were monitored weekly by FACS analysis, with 100% CD4+ T cells present by 6 weeks in cultures receiving IL-16 and IL-2.

selective immune reconstitution of CD4+ T cells from peripheral populations. IL-16 is a growth factor for CD4+ T cells, inducing IL2R expression and priming CD4+ T cells to proliferate in response to low concentrations of IL-2 (manuscript submitted). Treatment of PBMCs from HIV-1 infected individuals with IL-16 and IL-2 results in selective expansion of CD4+ T cells *in vitro* (see figure) and restores antigen specific proliferation. Thus, exogenous administration of IL-16 might have a dual effect of expanding functional peripheral blood CD4+ T cells while preventing virus replication in CD4+ T cells.

GREGORY A. VIGLIANT¹,
NEREIDA A. PARADA²,
JOSEPH W. MACIASZEK³,
HARDY KORNFELD², DAVID M. CENTER² &
WILLIAM W. CRUIKSHANK²

¹Department of Microbiology and ²The Pulmonary Center, Boston University School of Medicine, Boston, MA 02118 and ³The Program in Virology and Immunology, University of Massachusetts Medical Center, Worcester, MA 01605

- Zhou, P. *et al.* Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: Inhibition of mRNA expression. *Nature Med.* 3, 659-664 (1997).
- Maciaszek, J.W. *et al.* IL-16 Represses HIV-1 Promoter Activity. *J. Immunol.* 158, 5-8 (1997).
- Laberge, S. *et al.* Histamine-induced secretion of lymphocyte chemoattractant factor from CD8+ T cells is independent of transcription and translation: Evidence for constitutive protein synthesis and storage. *J. Immunol.* 155, 2902-2910 (1995).